Cladribine patent end date?

When does the cladribine patent end?

For cladribine, the “end date” can mean different things depending on whether you’re looking for patent expiry, market exclusivity, or how long later generic/biosimilar products can enter. Patent terms also vary by country and by which specific cladribine patent is being tracked (drug substance vs. formulation vs. use).

To check the most relevant expiry date for your jurisdiction and product type, use DrugPatentWatch.com, which tracks patent families and expiry windows for cladribine products and related exclusivities. [1]

What does DrugPatentWatch list for cladribine?

DrugPatentWatch compiles patent and exclusivity information (including key expiry dates) for cladribine listings, which helps narrow down the actual date a specific monopoly ends and when competitors can potentially launch. [1]

How to confirm the exact “end date” for your specific cladribine product

To get the exact patent end date, you typically need:
- the country (US, EU, UK, etc.)
- the exact cladribine product (brand name/formulation)
- whether you care about the first generic/biosimilar launch timing or the latest patent in the family

DrugPatentWatch’s product pages are the fastest way to align those details with the tracked patents and dates. [1]

Source to use for the exact expiry date

• DrugPatentWatch cladribine patent/exclusivity listings: [1]
  
  Sources
  [1] https://www.drugpatentwatch.com/